The following is a Sponsored Resource. The sponsor of this content has sole editorial control.

Early Breast Cancer:
Ready for AROMASIN?

If you are postmenopausal and have been taking tamoxifen for 2 to 3 years after early-stage breast cancer, you now have another treatment option.

For 20 years, tamoxifen has been the standard adjuvant hormonal therapy following initial treatment for estrogen-dependent early breast cancer. Adjuvant treatment for breast cancer is a treatment given after surgery, radiation, or chemotherapy. Although tamoxifen has benefits, studies show that switching to an aromatase inhibitor (AI) may also have benefits.

A recent study has shown that switching to AROMASIN after 2 to 3 years of tamoxifen can help reduce the risk of breast cancer recurrence compared with staying on tamoxifen for 5 years. It is important to note that no survival benefit was seen over tamoxifen therapy. More details about the study are available on this site.

Who May Benefit From AROMASIN

AROMASIN therapy is approved for women who:

  • Are postmenopausal and
  • Have had estrogen-receptor positive early breast cancer and
  • Have taken tamoxifen for at least 2 to 3 years

If your doctor switches you to AROMASIN, you'll take it instead of tamoxifen. You continue taking AROMASIN until you reach a total of 5 years of adjuvant treatment with the two drugs.

AROMASIN for Advanced Breast Cancer

AROMASIN may also be used to treat postmenopausal women with advanced breast cancer that have not responded or stopped responding to tamoxifen.